Wittycell: Outwitting the immune response
As vaccines become more targeted with regard to the antigens they use and more varied in the range of diseases they address, new adjuvants that can boost the immune response against a chosen antigen are becoming more important. Wittycell S.A.S. is developing adjuvants that stimulate natural killer T cells that the company says can be optimized for a partner's vaccine.
"The whole industry is waiting